Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;15(28):22972-22988.
doi: 10.1039/d5ra03317a. eCollection 2025 Jun 30.

Copper(ii) chelates of a coumarin-based acyl hydrazone ligand: structural characterization and computational evaluations for prospective applications in antimicrobial, antiviral, antioxidant, and anticancer therapies

Manar S Mahfouz  1 , Amira A M Ali  1 , Magdy Shebl  1 , Omima M I Adly  1 , R Fouad  1
Affiliations

Copper(ii) chelates of a coumarin-based acyl hydrazone ligand: structural characterization and computational evaluations for prospective applications in antimicrobial, antiviral, antioxidant, and anticancer therapies

Manar S Mahfouz et al. RSC Adv. .

Abstract

This study represents the synthesis and comprehensive characterization of four novel copper(ii) chelates (CuR, CuRCT, CuH, and CuHCT) derived from a newly developed coumarin-based acyl hydrazone ligand (HCBH). The chelates were prepared using multidisciplinary synthetic routes, including reflux and hydrothermal methods with or without surfactant assistance, resulting in distinct mono- and binuclear structures with nanoscale morphologies. Structural analyses confirmed that all copper complexes possess tetrahedral geometries, with ligand coordination modes varying between tridentate and tetradentate depending on the synthetic method. TEM imaging revealed unique morphologies for each chelate, and the successful dispersion of the bioactive CuH chelate into silica yielded a porous nanostructured drug delivery system. Biological evaluations revealed promising antimicrobial activity, particularly for CuHCT against E. coli and S. aureus, and for CuRCT against B. subtilis and C. albicans. Antioxidant assays showed that CuRCT and CuHCT exhibited superior activity compared to other complexes and standard ascorbic acid. CuH demonstrated potent cytotoxicity against HepG-2 and MCF-7 cancer cell lines, comparable to cisplatin, while maintaining moderate toxicity toward normal Vero cells (CC50 = 43.34 ± 1.98 μg ml-1). Although the antiviral activity of CuH against HAV was weak, in vitro release studies of CuH-silica composites confirmed controlled release behavior, supporting its potential as a nanodrug delivery system. Density Functional Theory (DFT) and molecular docking analyses corroborated the biological findings, with favorable interactions observed between the compounds and CDK2 kinase. Collectively, these results highlight CuH as a highly promising candidate for further preclinical evaluation, especially in cancer therapy, with silica-based dispersion enhancing its potential as a nanocarrier for targeted drug delivery.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Scheme 1
Scheme 1. Schematic representation of hydrazone ligand (HCBH).
Fig. 1
Fig. 1. TGA–DTA curves of CuR, CuRCT, CuH and CuHCT nano-chelates.
Fig. 2
Fig. 2. UV-vis spectra of CuR, CuRCT, CuH and CuHCT nano-chelates.
Fig. 3
Fig. 3. TEM images of CuR, CuRCT, CuH and CuHCT nano-chelates.
Scheme 2
Scheme 2. The schematic mechanism of the possible formation of CuRCT and CuHCT nano-chelates.
Fig. 4
Fig. 4. IC50 of HCBH, CuR, CuRCT, CuH, CuHCT nano-chelates and standard ascorbic acid at 30 min and 60 min.
Fig. 5
Fig. 5. Relation between cell viability and concentration of HCBH, CuR, CuRCT, CuH, and CuHCT nano-chelates.
Fig. 6
Fig. 6. The profile release of CuH nano-drug from silica xerogel matrix; (inset) the relation between % release of CuH nano-drug and time.
Fig. 7
Fig. 7. Molecular electrostatic potential (MEP) map of the HCBH and its copper chelates.
Fig. 8
Fig. 8. 3D representation of the hydrogen bonding between the studied compounds and the amino acid residues of the target protein (pdb ID: 3IG7).
See this image and copyright information in PMC

References

    1. Dyson P. J. Sava G. Metal-based antitumor drugs in the post genomic era. Dalton Trans. 2006;16:1929–1933. - PubMed
    1. Saif M. El-Shafiy H. F. Mashaly M. M. Eid M. F. Nabeel A. I. Fouad R. Hydrothermal preparation and physicochemical studies of new copper nano-complexes for antitumor application. J. Mol. Struct. 2018;1155:765–775.
    1. Gao L. Wang F. Chen Y. Li F. Han B. Liu D. The antithrombotic activity of natural and synthetic coumarins. Fitoterapia. 2021;154:104947. - PubMed
    1. Shebl M. Ali T. E. Assiri M. A. Novel mononuclear Cu(II), Ni(II), and Co(II) complexes of coumarinyl-pyrazolyl-thiazole thiosemicarbazone: Synthesis, characterization, and biological evaluation. Appl. Organomet. Chem. 2025;39:e7948.
    1. Benazzouz-Touami A. Ighilahriz k. Makhloufi-Chebli M. Hadhoum N. -Bernard Behr J. Chouh A. Synthesis, biological evaluation, ADMET studies, and molecular docking of novel coumarin–isoxazole derivatives as dual inhibitors of Hsp90 protein and acetylcholinesterase enzyme. J. Mol. Struct. 2025;1333:141776.

LinkOut - more resources